News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gentium S.p.A. Receives European Medicines Agency Orphan Drug Designation For Defibrotide For The Prevention Of GvHD


11/19/2013 9:11:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VILLA GUARDIA, Italy, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Commission ("EC") has granted Orphan Drug Designation to Defibrotide for the prevention of Graft versus Host Disease ("GvHD"). The designation follows a positive opinion released by the Committee for Orphan Medicinal Products ("COMP") of the European Medicines Agency ("EMA"), on October 10, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES